MDACC Study No:2012-0681 ( NCT No: NCT01623349)
Title:Phase I study of the oral PI3kinase inhibitor BKM120 or BYL719 and the oral PARP inhibitor olaparib in patients with recurrent triple negative breast cancer or high grade serous ovarian cancer
Principal Investigator:Shannon Westin
Treatment Agent:AZD2281; BKM120; BYL719
Study Status:Closed
Study Description:The goal of this Phase 1 clinical research study is to learn the highest
tolerable dose of the combination of the drugs BKM120 and Lynparza™ (olaparib)
or BYL719 and olaparib that can be given to patients with recurrent breast or
ovarian cancer. The safety of these drugs will also be studied.

BKM120, BYL719, and olaparib are both designed to block the growth and division
of cancer cells, which may cause the cells to die.
Hide details for General InformationGeneral Information

Disease Group:Breast; Ovary
Phase of Study:Phase I
Treatment Agents:AZD2281
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Dana Farber Cancer Institute
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Shannon Westin
Dept:Gynecologic Oncology
For Clinical Trial Enrollment:713-794-4314
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults